GAVI

1
Strategic issues for consideration
Focus efforts on strategic advantage
GAVI
The Vaccine Fund
2
Increase supply of priority vaccines
Combination DTPhepB vaccine market trend 2001 -
2006
1.80
60
1.80
1.50
50
1.50
1.20
40
1.20
millions of doses
price per dose
.90
30
.90
.60
20
.60
.30
.30
10
2005
2006
2004
2002
2003
2001
3
Strategic issues for consideration

• GAVI and the Vaccine Fund have had success in
  several areas in the last several years. The
  most successful initiatives share two
  characteristics
• Innovative use of time limited, step up
  investments to change a market dynamic (e.g., new
  entrants on Hep B, Hib, hopefully lower costs for
  ADIP vaccines) and
• GAVI and the VF were tightly coordinated to link
  funding with active support and monitoring (e.g.,
  execution of ISS funding, DQA, FSP)
• On the other hand in some cases where GAVI has
  not enlisting financial support from the Vaccine
  Fund, limited progress has been made (e.g.,
  alignment with polio and measles, human
  resources)
• Looking forward over the longer term, both GAVI
  and the Vaccine Fund are facing many challenges
  and opportunities. The best prioritization might
  be to favor catalytic and coordinated investments
  not being addressed by others. For example time
  limited, step up investments addressing
• Specific system barriers (e.g., availability of
  information, training)
• Access to financing barriers at country level
  (e.g., IDA buy down, CMM)
• Shared initiatives with other global alliances
  (e.g., Polio, Measles)
• These opportunities might require tighter
  coordination between management of GAVI
  Secretariat and the Vaccine Fund

4
Strategic issues for consideration
Selected examples of possible longer-term
strategic choices
5
Next steps

• Develop an investment case framework for GAVI and
  the Vaccine Fund based on country needs (vaccines
  as well as service delivery)
• Develop financing strategy, for example
• look for time-limited investments that facilitate
  long-term sustainable health systems
• new financing mechanisms
• Develop further the options for GAVI/Vaccine Fund
  coordination

6
Investment case framework
7
Timeline